Joel D Leverson Selected Research

navitoclax

1/2022	Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
11/2020	Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
10/2020	Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL -BAX interaction.
1/2019	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
1/2019	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
1/2019	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.
1/2019	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
4/2017	From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
1/2016	Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors.
1/2016	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joel D Leverson Research Topics

Disease

38	Neoplasms (Cancer) 01/2022 - 04/2005
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2013
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 03/2014
6	Multiple Myeloma 11/2021 - 10/2015
5	Leukemia 01/2020 - 03/2015
4	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 11/2009
4	Lymphoma (Lymphomas) 01/2020 - 02/2013
4	Lung Neoplasms (Lung Cancer) 11/2018 - 01/2015
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 07/2015
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 01/2022
2	Carcinogenesis 01/2021 - 04/2005
2	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 01/2017
2	Breast Neoplasms (Breast Cancer) 01/2019 - 08/2015
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Disease Progression 01/2022
1	Synovial Sarcoma (Synovioma) 05/2021
1	Triple Negative Breast Neoplasms 11/2020
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2019
1	Hypersensitivity (Allergy) 01/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2015
1	Lymphadenopathy 10/2015
1	Colorectal Neoplasms (Colorectal Cancer) 07/2015
1	Neutropenia 03/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2015
1	Thrombocytopenia (Thrombopenia) 10/2014
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2014
1	Genomic Instability 09/2007
1	Weight Loss (Weight Reduction) 06/2005

Drug/Important Bio-Agent (IBA)

26	venetoclaxIBA 05/2022 - 02/2013
16	navitoclaxIBA 01/2022 - 12/2011
16	Proteins (Proteins, Gene)FDA Link 07/2021 - 09/2007
5	Pharmaceutical PreparationsIBA 11/2018 - 01/2016
3	Phosphotransferases (Kinase)IBA 11/2018 - 06/2005
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 11/2020 - 01/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2020 - 01/2015
2	cobimetinibIBA 01/2020 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2005
2	Small Interfering RNA (siRNA)IBA 08/2015 - 04/2005
2	A-1155463IBA 07/2015 - 10/2014
2	Docetaxel (Taxotere)FDA Link 03/2015 - 01/2015
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	SenotherapeuticsIBA 01/2022
1	enasidenibIBA 01/2022
1	ibrutinibIBA 12/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 12/2021
1	MTOR InhibitorsIBA 11/2021
1	S63845IBA 05/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 11/2020
1	ABT-414IBA 11/2020
1	A-1331852IBA 10/2020
1	Etoposide (VP 16)FDA LinkGeneric 10/2020
1	CytokinesIBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	Drug CombinationsIBA 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	EWS-FLI fusion proteinIBA 01/2019
1	olaparibIBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	Coenzyme A (CoA)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	Myeloid Cell Leukemia Sequence 1 ProteinIBA 11/2017
1	bcr-abl Fusion ProteinsIBA 01/2016
1	Bortezomib (Velcade)FDA Link 01/2016
1	alvocidib (flavopiridol)IBA 08/2015
1	A-1210477IBA 08/2015
1	CamptothecinIBA 01/2015
1	BenzimidazolesIBA 01/2015
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2009
1	UbiquitinIBA 09/2007
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2005
1	Sirolimus (Rapamycin)FDA Link 06/2005
1	Glucose (Dextrose)FDA LinkGeneric 06/2005
1	Polo-Like Kinase 1IBA 04/2005
1	AgarIBA 04/2005

Therapy/Procedure

21	Therapeutics 05/2022 - 04/2005
7	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
1	Chemoradiotherapy 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 05/2021